Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

Author： Gnant Michael Baselga Jose Rugo Hope S. Noguchi Shinzaburo Burris Howard A. Piccart Martine Hortobagyi Gabriel N. Eakle Janice Mukai Hirofumi Iwata Hiroji Geberth Matthias Hart Lowell L. Hadji Peyman El-Hashimy Mona Rao Shantha Taran Tetiana Sahmoud Tarek Lebwohl David Campone Mario Pritchard Kathleen I.

Publisher： Oxford University Press

ISSN： 1460-2105

Source： Journal of the National Cancer Institute, Vol.105, Iss.9, 2013-05, pp. : 654-663

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

By Beaver Julia A Park Ben H

Future Oncology, Vol. 8, Iss. 6, 2012-06 ,pp. : 651-657

Future Medicine

Access to resources Recommend Favorite

Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression

By Park Yong

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1192-1199

Humana Press, Inc

Access to resources Recommend Favorite

Effect of the timing of surgery on the fracture healing process and the expression levels of vascular endothelial growth factor and bone morphogenetic protein2

Experimental and Therapeutic Medicine, Vol. 8, Iss. 2, 2014-01 ,pp. : 595-599

Spandidos Publications

Access to resources Recommend Favorite

Myeloma bone disease

By Mundy G.R.

European Journal of Cancer, Vol. 34, Iss. 2, 1998-02 ,pp. : 246-251

Elsevier

Access to resources Recommend Favorite

Inhibitory effect of bone morphogenetic protein-2 on the proliferation of giant cell tumor of bone stromal cells in vitro

Experimental and Therapeutic Medicine, Vol. 11, Iss. 1, 2016-01 ,pp. : 309-314

Spandidos Publications

Access to resources Recommend Favorite